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Abstract
Background: Melioidiosis, infection by Burkholderia pseudomallei, is an important but frequently under-recognised
cause of morbidity and mortality in Southeast Asia and elsewhere in the tropics. Data on the epidemiology of
paediatric melioidosis in Cambodia are extremely limited.
Methods: Culture-positive melioidosis cases presenting to Angkor Hospital for Children, a non-governmental
paediatric hospital located in Siem Reap, Northern Cambodia, between 1st January 2009 and 31st December 2013
were identified by searches of hospital and laboratory databases and logbooks.
Results: One hundred seventy-three evaluable cases were identified, presenting from eight provinces. For Siem
Reap province, the median commune level incidence was estimated to be 28-35 cases per 100,000 children <15 years
per year. Most cases presented during the wet season, May to October. The median age at presentation was 5.7 years
(range 8 days–15.9 years). Apart from undernutrition, co-morbidities were rare. Three quarters (131/173) of the children
had localised infection, most commonly skin/soft tissue infection (60 cases) or suppurative parotitis (51 cases). There
were 39 children with B. pseudomallei bacteraemia: 29 (74.4%) of these had clinical and/or radiological evidence of
pneumonia. Overall mortality was 16.8% (29/173) with mortality in bacteraemic cases of 71.8% (28/39). At least seven
children did not receive an antimicrobial with activity against B. pseudomallei prior to death.
Conclusions: This retrospective study demonstrated a considerable burden of melioidosis in Cambodian children.
Given the high mortality associated with bacteraemic infection, there is an urgent need for greater awareness amongst
healthcare professionals in Cambodia and other countries where melioidosis is known or suspected to
be endemic. Empiric treatment guidelines should ensure suspected cases are treated early with appropriate
antimicrobials.
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Background
Meliodiosis, infection by the Gram negative environ-
mental bacterium Burkholderia pseudomallei, is an im-
portant but frequently under-recognised cause of
morbidity and mortality in Southeast Asia and elsewhere
in the tropics [1, 2]. It was recently estimated that there
might be as many as 165,000 cases of meloidosis world-
wide in 2015, an annual incidence rate of 5 per 100,000
people at risk [3]. Infection occurs following per-
cutaneous inoculation, inhalation, or ingestion of the or-
ganism. The spectrum of infections is broad, ranging
from minor skin or soft tissue infection to pneumonia
and bacteraemia with a high mortality. Parotitis is a
common presentation in children in Southeast Asia
[4–6]. This may be the result of ingestion or aspiration of
B. pseudomallei-contaminated water sources [7]. Standard
treatment of melioidosis consists of an acute phase
consisting of intravenous ceftazidime or a carbapenem
for at least 10 days followed by an eradication phase
consisting of oral co-trimoxazole or co-amoxiclav for
at least 12 weeks [8].
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To date, there are few data on the epidemiology of
melioidosis in Cambodia, a low-income country with a
2008 population of 13.4 million (including 4.5 million
children aged less than 15 years) [9]. The country has
extremely limited microbiology laboratory capacity.
Vlieghe and colleagues described 58 adult cases present-
ing to a single hospital in the capital, Phnom Penh, be-
tween July 2007 and January 2010 [10]. Angkor Hospital
for Children (AHC), a non-governmental hospital lo-
cated in Siem Reap province, identified a total of 39
paediatric melioidosis cases over an overlapping time
period (October 2005 to December 2008), following the
opening of a diagnostic microbiology laboratory within
the hospital [11]. Although these figures are lower than
the numbers of cases seen annually in neighbouring
Thailand [12], more recently, B. pseudomallei has been
reported to account for 74% of suppurative parotitis [6],
and 7.9% of culture-positive bacteraemia [13] seen in
AHC, further evidence that melioidosis is likely to have
been grossly underdiagnosed in Cambodia. Recent mod-
elling has suggested that the true number of cases of
melioidosis nationally may be around 2000 per year [3].
Assuming that between 5 and 15% of melioidosis occurs
in children [4], 100–300 paediatric cases per year would
be expected across the whole country.
The aim of this retrospective study was to describe the
epidemiology, clinical presentations, treatment and out-
comes of melioidosis in Cambodian children presenting
to AHC over a 5-year period.
Methods
Study site
Cambodia has a tropical climate with monsoon rains
occuring between May and October each year. Siem
Reap province is located in the northwest of the country
and comprises 12 districts and 100 communes. The
province had a total population of 896,443, including
322,857 children aged <15y, according to the 2008 na-
tional census [9]. Angkor Hospital for Children is one of
two paediatric hospital located in Siem Reap province.
This non-governmental hospital comprises a main site
in Siem Reap city and, since 2010, a smaller satellite
clinic (SC) located in Sot Nikom district referral hos-
pital, 35 km from the main hospital. AHC provides free
secondary and tertiary level care to children aged
<16 years with no geographic restriction. There are ap-
proximately 180,000 patient presentations and 7000 ad-
missions per year; around 2/3 of children admitted
reside in Siem Reap province. A microbiology laboratory
is located at the main hospital and specimens are trans-
ported from the satellite clinic for processing on a daily
basis. Microbiology specimens are routinely processed to
identify B. pseudomallei infection as previously described
[11]. Briefly, 1–4 ml blood specimens are cultured for up
to 7 days in 20 ml tryptone soya broth (Oxoid, UK) plus
0.05% sodium polyanethol sulphonate (Sigma-Aldrich,
UK). Bottles are inspected daily with sub-culture if the
broth is cloudy and additional blind sub-cultures at 24 h
and 7 days. Suspected B. pseudomallei colonies are con-
firmed by Gram stain, a B. pseudomallei latex agglutin-
ation test [14] and/or API 20NE (bioMerieux, France),
plus resistance to colistin and gentamicin discs (Oxoid).
Non-blood specimens are cultured onto a range of media,
including Ashdown’s agar, and B. pseudomallei identified
as described for blood cultures. AHC clinical guidelines
cover identification and treatment of suspected and
culture-confirmed melioidosis. Specifically, a blood cul-
ture is recommended in all cases of suspected melioidosis
plus a throat swab in those with suspected pneumonia or
sepsis and a urine culture in those with suspected sepsis.
Abdominal ultrasound scanning is recommended if vis-
ceral involvement is suspected. Ceftazidime and/or imipe-
nem were available for empiric treatment throughout the
study period.
Case definitions
A melioidosis case was defined as a patient in whom B.
pseudomallei had been isolated from at least one clinical
specimen collected between 1st January 2009 and 31st De-
cember 2013. Cases were identified by manual searches of
laboratory logbooks and electronic databases. Results of
these searches were cross-checked against the hospital elec-
tronic patient information system to identify and correct
discrepancies. The English language medical records of
cases were retrieved and clinical, laboratory, and radiology
data extracted onto a standardised case report form (CRF).
Cases were defined as localised or disseminated as de-
scribed elsewhere [11]. Briefly, localised infection was de-
fined as a single anatomic focus of infection whereas
disseminated infection was defined as localised infection
in two or more discrete anatomic areas and/or B. pseudo-
mallei bacteraemia. Suppurative parotitis was defined as
infection of the parotid confirmed by ultrasound or surgi-
cal findings: cases clinically diagnosed as “parotitis” with-
out such confirmation were categorised as skin/soft tissue
infection. Secondary foci of infection were assigned by re-
view of clinical, lab, and radiological data. Lymph node ab-
scesses were considered secondary foci if there was a
culture postive skin/soft tissue infection (SSTI) in an ana-
tomically relevant location; SSTI were considered second-
ary foci in pneumonia cases; and otitis/mastoiditis was
considered secondary to supurative parotitis. Cases in
whom symptoms had been present for >2 months at pres-
entation were categorised as chronic melioidosis [15].
Data management
Completed CRFs were single-entered into a password
protected database (Access 2013, Microsoft, USA). The
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data were checked for errors by systematic plotting of
numerical datapoints and review of all outlying values
plus a review of a subset of CRFs. Data were analysed
using R version 3.20 [16]. Maps were drawn with QGIS
version 2.8 [17], using Open Development Cambodia
basemaps containing commune level population data
from the 2008 Cambodian National Census [9, 18]. Nu-
tritional status was assessed in children aged 0–10 years
by calculating weight-for-age z-scores using WHO
AnthroPlus version 1.0.4 [19]. Absence of height data
precluded assessment of nutritional status in older chil-
dren. Non-normally distributed continuous variables
were described by the median, inter-quartile range
(IQR), and overall range. Proportions were compared by
the Chi-squared or Fisher’s exact test, as appropriate.
Two-tailed p-values of <0.05 were used to indicate stat-
istical significance in all comparisions.
Results
Between 1st January 2009 and 31st December 2013, B.
pseudomallei was identified in specimens from 176 pa-
tients. Medical records were available for review in 173
cases and these were included in the subsequent ana-
lyses (Additional file 1: Figure S1). Nineteen cases were
identified in 2009, with between 35 and 44 cases in sub-
sequent years (Additional file 1: Figure S2). Cases pre-
sented from eight provinces, with almost three quarters
(72.8%; 126) of cases residing in Siem Reap province
(Additional file 1: Figure S3). The distribution of cases
within Siem Reap province (Additional file 1: Figure S4)
was similar to the overall distribution of hospital
admissions (Additional file 1: Figure S5) over the same
time period. Over eighty percent (146/173) of melioid-
osis cases presented during the wet season, May to
October (Fig. 1).
The median age at presentation was 5.7 years (IQR
3.1–9.5; range 0.02–15.9; Additional file 1: Figure S6).
There were three neonatal cases and the youngest pa-
tient was 8 days old at first presentation. Seventy-four
(42.8%) children were female. Only five children had sig-
nificant co-morbidities documented: two with thalassae-
mia and one each with chronic renal failure, probable
acute lymphoblastic leukaemia (ALL), and systemic
lupus erythematosus (SLE). Additionally, one child may
have had an underlying immunodeficiency given two
previous episodes of Chromobacterium violaceum sepsis
[20]. None of the children were known to be diabetic at
presentation, or were subsequently diagnosed as such. A
Fig. 1 Seasonality of melioidosis case presentation at Angkor Hospital for Children, 2009–2013
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weight measurement was available in 131/134 children
aged 0–10 years and 48.1% (63/131) of these had
weight-for-age z-scores of < −2, indicating that they were
moderate to severely underweight.
One hundred and fifty children (86.7%) presented dir-
ectly to AHC from home, with 20 presenting following
attendance at another healthcare facility (data missing in
three cases). The median duration of symptoms at pres-
entation was 7 days (IQR 5–14; range 1 day–7 months).
Six children were categorised as having chronic melioid-
osis at presentation. Almost a quarter (42/173; 24.3%) of
children had evidence of disseminated infection: most
commonly bacteraemia with clinical or radiological evi-
dence of pneumonia (Table 1). A head and/or neck le-
sion was identified in 112/173 (64.7%) children. B.
pseudomallei was isolated from 197 specimens: 146 pus/
swab cultures, 43 blood cultures, 5 sputum cultures, and
3 throat swab cultures (2 from children with pneumonia
and 1 from a child with parotitis). The organism was iso-
lated from a median of one (range 1–6) specimen per
patient. Only 57 (32.9%) children had a blood culture
taken at presentation; this was more likely in medical
admissions (43/57, 75.4%) compared with surgical ad-
missions (14/116, 12.1%), p < 0.0001. None of the chil-
dren admitted to hospital had an abdominal ultrasound
scan result recorded in the clinical notes or hospital
radiology database.
Twenty-nine (16.8%) children died and 23 (79.3%) of
these died within a week of presentation (the median
time to death was 1 day from presentation). Three of the
deaths could not be clearly attributed to melioidosis: one
in-hospital death may have been due to a ventilator-
associated pneumonia, one early post-discharge death in
the child with probable underlying ALL, and one late
(>6 months) post-discharge death in one of the neonatal
bacteraemia/pneumonia cases. Bacteraemia was signifi-
cantly associated with death: 28/39 (71.8%) of bacter-
aemic children died compared with 1/134 (0.7%) of non-
bacteraemic children (p < 0.0001).
Ninety-five (54.9%) children were admitted to hospital
and the 78 remaining children were managed entirely in
the out-patient department. In those admitted, the me-
dian duration of admission was 9 days (IQR 2–13; range
0–70). Twenty-six children died during hospitalisation
and one was discharged against medical advice. In those
hospitalised, 25/91 (27.5%) were treated with inotropes
and/or steroids for management of haemodynamic
instability and 25/94 (26.6%) required mechanical venti-
lation. Fifty-one (53.7%) hospitalised children had a sur-
gical procedure, mostly incision and drainage of an
abscess. Antimicrobial treatment data were available on
91/95 admitted children. On admission, empiric treat-
ment was variable and most commonly included ceftri-
axone (35 children) and/or cloxacillin (32 children).
Nineteen children were empirically started on ceftazi-
dime. Overall, 81 of the admitted children received cef-
tazidime and/or imipenem for a median of 9 days (IQR
5–13; range 0–52). The median time from presentation
to starting either ceftazidime or imipenem was 3 days
(IQR 1–3; range 0–52). Seven of the children who died
in hospital did not receive ceftazidime or imipenem,
with antimicrobial treatment details missing in another
four: six died within 24 h of presentation and melioid-
osis was not suspected in the seventh case until a posi-
tive pus culture was obtained 13 days after admission.
All 68 children discharged from in-patient treatment
received follow-on oral eradication treatment. Most
children received a single oral antibiotic: 41 received co-
amoxiclav (median duration 65 days (IQR 32–110; range
4–202)), 11 received co-trimoxazole (median duration
32 days (IQR 23–87; range 11–105)), and one received
doxycycline (for 94 days). The remaining children received
various combinations of co-amoxiclav, co-trimoxazole,
and doxycycline. Four children were readmitted following
discharge: none had a microbiologically-proven melioid-
osis relapse but one child was empirically re-treated with
ceftazidime for 11 days.
Of the 78 children treated entirely as out-patients, all
but one had localised melioidosis. A minor surgical
procedure was performed in 63 (80.8%) children. Em-
piric antimicrobial treatment was highly variable but
Table 1 Foci of infection in 173 melioidosis cases presenting to
Angkor Hospital for Children, 2009–2013
Number Percent
Principal focus of infection
Bacteraemic 39 22.5
Pneumonia 29 16.8
No focus found 6 3.4
Parotitis 2 1.2
Skin/soft tissue infection 2 1.2
Non-bacteraemic/Blood culture not done 134 77.5
Skin/soft tissue infection 60 34.6
Parotitis 51 29.4
Lymph node abscessa 15 8.6
Pneumonia 4 2.3
Vaginal discharge 2 1.2
Otitis/mastoiditis 1 0.6
Periorbital cellulitis 1 0.6
Secondary foci of infection (in addition to a primary focus)
Skin/soft tissue infection 4
Otitis/mastoiditis 2
Lymph node abscess 5
a14 head/neck and 1 lower limb
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commonly included cloxacillin (49 children). Eighteen
children were treated empirically with co-amoxiclav and
six with co-trimoxazole. Overall, 67 (85.9%) of these
children received an oral antibiotic with activity against
B. pseudomallei. Co-amoxiclav monotherapy was pre-
scribed for 33 children (median 82 days (IQR 28–109;
range 6–137)) and co-trimoxazole monotherapy was pre-
scribed for 19 children (median duration 21 days (IQR
15–79; range 8–176)). The median starting dose co-
amoxiclav was 250 mg (IQR 250–500; range 170–1000),
equating to 20 mg/kg/dose (IQR 15–24; range 12–30). For
co-trimoxazole, the median starting dose (trimethoprim +
sulphamethoxazole combined) was 360 mg (IQR 240–
480; range 240–720), equating to a sulphamethoxazole
dose of 20 mg/kg/dose (IQR 16–21; range 15–25). The
other 15 children were prescribed combinations of co-
amoxiclav, co-trimoxazole, and doxycycline.
Excluding the 26 children who died in hospital, the
median duration of follow-up from presentation to final
hospital discharge or out-patient visit was 39 days (IQR
10–91; range 0–224). Duration of follow-up was
3 months or more in 50 children but successful comple-
tion of at least 12 weeks of treatment and symptomatic
recovery could be documented definitively in only 20
cases. An additional 32 children were seen in the hos-
pital out-patient department at least 4 weeks following
their final melioidosis-related visit (median time from
final melioidosis-related visit to most recent out-patient
visit: 710 days (range 56–1777). Of these, 12 were
treated with a single agent oral-only regimen (seven co-
amoxiclav and five co-trimoxazole) and eight treatment
courses were of <12 weeks duration.
Disease incidence was estimated for the 61 communes in
Siem Reap province with at least one melioidosis case over
the study period, including the 125 cases aged <15 years
and using commune <15 year-old population data from the
2008 national census as the denominator (Fig. 2). These 61
communes comprised 223,575 children aged <15 years
(69.2% of all children <15y in Siem Reap province). Over
the 5-year study period, the median commune-level
incidence was 53 per 100,000 children (IQR 31–74; range
8–214). The median annual commune-level incidence
ranged from 28 cases per 100,000 children (IQR 23–41;
range 8–103) in 2011 to 35 cases per 100,000 children
(IQR 27–55; range 15–129) in 2010 (Additional file 1: Fig-
ure S7). Overall incidence was re-calculated assuming that
the 39 non-included communes were truly melioidosis-
free. For the 5-year study period, this adjusted median level
commune incidence would be 30 per 100,000 children
(IQR 0–65; range 0–214).
Discussion
This study represents the most comprehensive descrip-
tion of paediatric melioidosis in Cambodia to date. The
data presented confirms the initial findings regarding
paediatric melioidosis in Cambodia [6, 11, 13]. The ma-
jority of cases occurred in the monsoon season, were
localised infections, and most children did not have
underlying co-morbidities. Along with the adult data
from Phnom Penh [10], the study highlights the wide
geographic distribution of cases within the country. Un-
fortunately, despite greater awareness of the disease at
AHC, the mortality in bacteraemic cases has not fallen
significantly since the first cases were described: it was
77.8% (7/9 cases) between 2005–2008 and 71.8% (28/39)
in the current study (2009–2013) [11]. Community-
based awareness programmes, focussed on understand-
ing disease risk factors and reducing time to presenta-
tion at hospital, may improve mortality. Consistent
availability of ceftazidime for empiric treatment of sus-
pected melioidosis is also critical: currently this may be
sub-optimal in Cambodia as a result of cost. For AHC,
the cost of a 1 g vial of ceftazidime is US$4.20, com-
pared with US$1.05 for a 1 g vial of ceftriaxone. To put
these costs in context, the GDP (gross domestic prod-
uct) per capita for Cambodia was US$735 in 2009, rising
to US$1020 in 2013 [21].
In Siem Reap province, the median annual incidence
was estimated to be between 28 and 35 cases per
100,000 children <15 years per year. This is lower than
the incidence in children in Ubon Ratchathani province,
Northern Thailand: 48 cases per 100,000 children <15 years
per year [12]. However, the Siem Reap figure is likely to be
an underestimate for several reasons. Firstly, AHC is one of
two paediatric referral hospitals in the province, meaning
an unknown number of cases are likely to have been admit-
ted and treated at the other facility. Secondly, microbiology
specimens were sent for culture at the discretion of the at-
tending clinician: this may have resulted in an underesti-
mate in the total number of cases and also the proportion
that were confirmed to be bacteraemic. Thirdly, given the
difficulties of transportation in rural Cambodia, seriously
unwell children may have been missed because of death
prior to reaching hospital. Finally, a single census popula-
tion estimate was used for the entire study period. None-
theless, the fact that 35–44 cases of culture-positive
melioidosis are being diagnosed at this single, relatively
small paediatric hospital suggests that the recent estimate
of 2000 cases per year in all age groups across the whole
country may be conservative assuming that the incidence is
similar in other parts of the country [3]. One other interest-
ing finding is that there appear to be some relative ‘hot-
spots’ of higher melioidosis incidence within the catchment
area of AHC. It is notable that one of these coincided with
the location of the AHC satellite clinic, suggesting the pos-
sibility of some referral and ascertainment bias, although
this could not explain the other ‘hot-spots’ identified. A bet-
ter understanding of the factors that contribute to such
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variations in incidence, for example whether this is related
to specific local environmental or climatic conditions, dif-
ferences in human behaviour or susceptibility, or the pres-
ence of unusually virulent bacterial strains, would be
invaluable to our understanding of the epidemiology of
melioidosis and the ecology of B. pseudomallei, and might
help to predict other places where melioidosis hot spots
could occur.
The study highlights the difficulties of empiric treat-
ment and follow-up in low-resource settings such as
Cambodia. Only 19/95 (20.0%) of the hospitalised chil-
dren were treated empirically with ceftazidime and at
least seven children did not receive an antibiotic active
against B. pseudomallei prior to death. The duration of
intensive treatment was also shorter than the recom-
mended minimum of 10 days in many cases [8]. Oral
antimicrobial dosing was variable: the median initial
co-amoxiclav dose of 20 mg/kg was adequate [8], but
the median initial co-trimoxazole dose of 20 mg/kg
(sulphamethoxazole component) was significantly lower
than the 30 mg/kg recommended in the Royal Darwin
Hospital paediatric melioidosis guideline [15]. Success-
ful completion of eradication treatment was only docu-
mented in 20/146 (13.7%) children surviving to hospital
discharge. Similarly poor adherence to follow-up has
been described in Indian children [22]. Creative models
for follow-up for such populations such as home- or
village-based review and monitoring of eradication
treatment may be required in rural areas. There is a
need for dedicated trials to determine the efficacy of
oral-only and/or shorter treatment protocols for mild
infections.
Fig. 2 Commune-level incidence of melioidosis per 100,000 children aged <15 years in Siem Reap province over the 5-year study period (2009–2013).
AHC: Angkor Hospital for Children; SC: AHC Satellite Clinic. Study data overlaid on the Open Development Cambodia basemap [18]
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Similar paediatric case reviews have been completed, for
example in Australia (45 cases between 1989 and 2013 [15]
and 8 cases between 1996 and 2006 [23]), India (11 cases
from 2007 to 2014 [22]) Malaysia (16 cases between 1976
and 2005 [24] and 13 cases between 2000 and 2003 [25]),
Singapore (17 children between 2002 and 2014) [26] and
Thailand (55 cases between 1979 and 1993 [27], 37 local-
ised cases between 1994 and 2006 [28], and 46 cases be-
tween 1990 and 1991 [29]). Broadly the findings are similar
in all studies. Around a third of cases presented with sup-
purative parotitis, which is in line with data from Thailand
[5]. However, the mortality in Northern Australian children
was significantly lower than in Cambodian children: 7% (3/
45) compared to 17% (29/173). A small number of Austra-
lian children presented with neurologic manifestations
(brainstem encephalitis). There was no evidence of neuro-
logic involvement in any of the Cambodian children but
there has been a single case of culture-confirmed B. pseu-
domallei meningitis at AHC since 2013.
The major limitation of the study was its retrospective
nature, resulting in limited ability to explore risk factors for
infection or poor outcome. Potentially important co-
morbidities and environmental exposures may not have
been documented reliably. Absence of abdominal ultra-
sound scan results meant that the frequency of intra-
abdominal organ involvement could not be established. It
was also not possible to explore the outcomes of children
treated exclusively with oral antibiotic regimens. This
would have been desirable as, to date, there are only scant
data to support such regimens [4, 30]. Finally, data were ob-
tained from a single hospital and so extrapolation of find-
ings to the wider population of Cambodia must be done
cautiously.
Conclusions
This retrospective study demonstrates a considerable bur-
den of melioidosis in Cambodian children. Given the high
mortality associated with bacteraemic infection, there is an
urgent need for greater awareness amongst healthcare
professionals in Cambodia and other countries where meli-
oidosis is known or suspected to be endemic. Empiric treat-
ment guidelines should ensure suspected cases are treated
early with appropriate antimicrobials. Attention should be
paid to optimising adherence to long eradication treatment
regimens following discharge from hospital.
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